Generic drug competition isnt won in the lab. Its won in the fine print.
Thats the quiet lesson behind the FDAs Orange Bookand the playbook generic manufacturers use to find timing, identify leverage points, and move faster than brand incumbents can re…

Biopharma hiring is broken in a very specific way: we keep treating IP as a department, not as an operating system.
Most organizations still recruit IP talent as if the work lives in a vacuumpatent agents here, freedom-to-operate counsel there, maybe a…

The generic cliff isnt a cliff at allits a deadline.
For pharma companies, the real race doesnt start when patents expire. It starts years earlier, when the clock is still quiet and the boardroom still has time to pretend the future is optional. Then…

Patent thickets are the quiet tax on innovationespecially in biologics.
If youve ever wondered why some blockbuster drugs seem to never really go generic, the answer is often not scienceits strategy. In a recent DrugPatentWatch piece, the focus is on…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after youve already spent the moneyafter the deal is signed, after the regulatory strategy is locked, after the launch timel…

Most teams treat formulation patents like a black box. Thats why they miss the design-around window.
In pharma, the real competitive advantage often isnt the active ingredientits the formulation. And yet, when companies evaluate formulation patents, ma…

Russias VED and SSM lists arent just regulatory paperworktheyre a timing mechanism. And for generic manufacturers, timing is everything.
Heres the agitation: in markets where reimbursement, tender eligibility, and procurement decisions hinge on officia…

Pharma pipelines dont fail because of science. They fail because of risk you didnt model.
Thats the uncomfortable truth behind many surprise launch delays, injunction threats, and expensive redesigns: the problem wasnt the drugit was the freedom to ope…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn Copy Into Competitive Moat
In generic drug land, the default playbook is familiar: file an ANDA, win on price, and let scale do the heavy lifting. But that strategy has a ceilingespecially as regulato…

Pharma IP teams dont get many heads up moments. But Russias patent-term extension landscape is one of those areas where being late can be expensivefast.
Heres the hook: if your company relies on Russia for meaningful revenue, you should treat patent-te…